MedTech regulatory signals in 2026: invisible to Apollo

On May 28, 2026, the first four modules of the European EUDAMED database became mandatory (Decision (EU) 2025/2371). A MedTech company that registers a device, obtains its CE marking, or notifies the ANSM (France’s medical products safety agency) of an activity leaves a public trace at every step. That trace says something no contact database can: this device is about to be sold.

A regulatory signal is the earliest buying signal in the medical device industry. It comes before the sales hire, the LinkedIn post, and the trade show booth, sometimes by several months. Horizontal prospecting tools (Apollo, Sales Navigator, ZoomInfo) are built on LinkedIn and company registries: EUDAMED, ANSM notifications, and the BOAMP (France’s official public procurement bulletin) aren’t part of their data coverage. This article covers three regulatory sources, what they reveal, why traditional B2B databases ignore them, and how to turn them into pipeline.

Why is a regulatory signal a buying signal?

A regulatory milestone marks a device’s shift from development to commercialization. It’s the exact moment its manufacturer needs a pipeline (it has to sell), or the moment a competitor enters your market (it’s about to launch). CE marking, under Regulation (EU) 2017/745, which has applied since May 26, 2021, is the gateway to the European market: without it, the device can’t be placed on the market.

This dynamic flips a classic qualification rule. A MedTech startup still in R&D, in clinical trials, or waiting for certification has no active sales team: it isn’t a prospect. The day it obtains CE marking, it goes from “can’t be qualified” to “hot window.” The regulatory signal is exactly that tipping point, made public and dated.

The transition period for Regulation 2017/745 amplifies the effect. Regulation (EU) 2023/607 extended the compliance deadlines to December 31, 2027, for higher-risk devices (Class III and implantable Class IIb) and to December 31, 2028, for other classes. Every recertification under the MDR is an observable product portfolio move, and therefore a conversation trigger.

What does EUDAMED contain, and what is public?

EUDAMED is the European database on medical devices, established by Regulations (EU) 2017/745 and 2017/746. It has six interconnected modules; the first four have been mandatory since May 28, 2026: actor registration, UDI/device registration, notified bodies and certificates, and market surveillance (European Commission, 2025). Part of the data can be freely searched on the Commission’s public website, with no subscription.

Public search lets you find a device by manufacturer, trade name, risk class, UDI-DI and Basic UDI-DI identifier, EMDN nomenclature, or intended medical purpose. The actor registration module assigns each economic operator a unique number, the SRN (Single Registration Number), which serves as the key linking a manufacturer to all its declared devices.

In practical terms, EUDAMED tells you “who makes what, in which risk class, and since when” across the European medical device market. UDI registration has been possible on a voluntary basis since October 2021: the most advanced manufacturers are already listed, even before the mandatory deadline. Cross-referencing a new EUDAMED entry with a directory of practitioners turns a registry line into a named sales target.

How do you read ANSM notifications and decisions in the Journal Officiel?

In France, the ANSM is the competent authority for medical devices. Every manufacturer, authorized representative, or distributor must notify it before placing a device on the French market; French manufacturers of Class I and custom-made devices must also declare their activity (ANSM, 2026). Because this notification comes before commercialization, the ANSM is the mandatory checkpoint for entering the national market.

The ANSM doesn’t just register. It centralizes materiovigilance (medical device incident reporting), can order a manufacturer to take corrective action, and can suspend or ban a device. These health enforcement decisions are published: a suspension at one vendor opens a competitive window with its customers, who need to find an alternative.

For a rep in the industry, there are two ways to read this. A recent ANSM notification signals a device arriving on the French market, meaning a manufacturer that’s about to prospect hospitals. A suspension decision signals a gap in a competitor’s offering, meaning an account to approach. Both are dated, public, and absent from traditional contact databases.

Why can’t Apollo, Sales Navigator, and ZoomInfo see these signals?

These platforms cover LinkedIn and company registries: profiles, job titles, headcount, funding rounds, and declared technologies. EUDAMED, ANSM notifications, decisions published in the Journal Officiel (France’s official gazette), and BOAMP tenders aren’t part of their data coverage. The differentiator isn’t the quality of the contact; it’s the nature of the source.

The consequence is structural. Prospecting built only on these tools detects a move once it becomes visible on LinkedIn: the Head of Sales hire, the founder’s post, the conference announcement. By then, the regulatory signal that preceded them is already several weeks old, and a competitor who was reading EUDAMED has gotten ahead. Timing is exactly what’s at stake in a hospital sales cycle of 6 to 24 months.

Reading regulatory sources doesn’t replace LinkedIn: it gets there first. The most predictive buying signal in the industry arrives first through a public registry, not a job change. The same logic applies to other horizontal tools on the market, as our analysis of what Apollo, Lusha, and ZoomInfo can’t see in the French hospital market points out.

How do you turn these signals into pipeline?

The value isn’t in any single source, but in cross-referencing. A device newly registered in EUDAMED, matched with the corresponding ANSM notification, the device’s specialty code, and the RPPS directory (France’s national registry of healthcare professionals), becomes a list of practitioners and facilities to target, with the right angle at the right time. This expert reading of public sources, which general-purpose tools don’t integrate, is the moat.

That’s the engine behind Radar in MedTech, offered by AgifyMD: cross-referencing regulatory registries, public procurement, and healthcare directories to deliver targets qualified on a signal, not cold lists. A French medical imaging MedTech company had several thousand radiologists qualified this way by cross-referencing LinkedIn, scientific publications, and the RPPS, where a standard contact database would have stopped at a few hundred visible profiles. If you sell medical devices and your monitoring stops at LinkedIn, let’s look together at which regulatory signals you’re missing.

The method comes down to three moves: identify the public milestones that precede a sale in your category, cross-reference them with a directory that ties them to a named decision-maker, and trigger outreach during the window when the need is active. CE marking, EUDAMED, and the ANSM provide the first move; the BOAMP, further downstream, confirms buying intent on the hospital side, as detailed in our guide to buying signals to decode in a BOAMP tender.

Frequently asked questions

Is EUDAMED free and open to the public?

Yes. EUDAMED has a public website, separate from the interface reserved for economic operators, accessible without a subscription through the European Commission. You can search for a device by manufacturer, trade name, risk class, UDI-DI or Basic UDI-DI identifier, EMDN nomenclature, and intended medical purpose. The most sensitive data remains restricted to authorities, but the public scope is enough to detect that a device is coming to market.

When does CE marking become an actionable signal?

As soon as it results in a public registration or notification. CE marking allows a device to be placed on the market; EUDAMED registration and the ANSM notification make it visible and dated. The window to act is short, from a few days to two weeks after publication, because that’s when the manufacturer is organizing its sales approach.

What’s the difference between an ANSM declaration and EUDAMED registration?

The ANSM operates at the national level: the prior notification is a condition for placing a device on the French market. EUDAMED operates at the European level: it centralizes operators, devices, and their certificates for the entire EU. A device sold in France appears in both, for different purposes. Cross-referencing the two makes detection more reliable and pins down the geography.

Do traditional B2B databases include EUDAMED?

No. Apollo, Sales Navigator, and ZoomInfo are built on LinkedIn and company registries. EUDAMED, ANSM notifications, and the BOAMP aren’t part of their coverage. That blind spot is exactly what makes these regulatory signals valuable: they aren’t in the tool everyone else uses.

When does the MDR transition period end?

Regulation (EU) 2023/607 extended the transition to Regulation 2017/745 until December 31, 2027, for higher-risk devices (Class III and implantable Class IIb) and until December 31, 2028, for other classes, subject to conditions. Every recertification in this window is an observable, dated product portfolio move.

Conclusion

The medical device industry leaves a public trace at every step that precedes a sale: CE marking, EUDAMED registration, ANSM notification, a decision in the Journal Officiel. These sources are free, dated, and structurally missing from horizontal contact databases. Three takeaways: the regulatory signal comes several weeks before the LinkedIn signal; its value comes from cross-referencing it with a directory that ties it to a decision-maker; and in a long hospital sales cycle, timing makes the difference between a reply and silence.

Expert reading of these registries has to be built; it can’t be improvised. To map out together the regulatory signals that matter for your device category, book a call.

---

This article is part of the guide to MedTech prospecting in France. Agify designs prospecting agents that read the public sources general-purpose tools ignore, for the medical device and healthcare industry.